Examining antidepressant drug response by smoking status: Why is it important and how often is it done?

Journal of Psychopharmacology

Volumn 25, Issue 10, 2011, Pages 1269-1276

  Weinberger, Andrea H ^a   McKee, Sherry A ^a   Picciotto, Marina R ^a   Mazure, Carolyn M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; depression; review; smoking; treatment

Indexed keywords

ALTINICLINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CYTISINE; FLUOXETINE; IMIPRAMINE; MECAMYLAMINE; NICOTINE; NICOTINE PATCH; NICOTINIC RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TC 5214; UNCLASSIFIED DRUG;

CLINICAL STUDY; CLINICAL TRIAL; DEPRESSION; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; NEUROMODULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SMOKING; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING;

EID: 82955194787     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110389347     Document Type: Review

References (57)

1. Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking: A national perspective. JAMA. 1990 ; 264: 1541-1545 (Pubitemid 20303383)
2. Diagnostic and Statistical Manual of Mental Disorders. 1994 ) Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association, Washington DC: American Psychiatric Association ; 1994 :
3. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990 ; 264: 2524-2528
4. Caldarone BJ, Harrist A, Cleary MA, Beech RD, King SL, Picciotto MR. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry. 2004 ; 56: 657-664 (Pubitemid 39446847)
5. Caldarone BJ, Karthigeyan K, Harrist A, Hunsberger JG, Wittmack E, King SL, et al. Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6J mice. Psychopharmacology. 2003 ; 170: 94-101 (Pubitemid 37372483)
6. Cohen J Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates ; 1988 :
7. Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary results from a multicenter clinical trial in generalized anxiety disorder. Psychiatry (Edgmont). 2009 ; 6: 26-31
8. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005a ; 29: 571-625 (Pubitemid 40755457)
9. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev. 2005b ; 29: 547-569 (Pubitemid 40755456)
10. Dierker L, Donny E. The role of psychiatric disorders in the relationship between cigarette smoking and DSM-IV nicotine dependence among young adults. Nicotine Tobacco Res. 2008 ; 10: 439-446 (Pubitemid 351385824)
11. Djuric VJ, Dunn E, Overstreet DH, Dragomir A, Steiner M. Antidepressant effects of ingested nicotine and female rats of finders resistant and sensitive lines. Phys Behav. 1999 ; 67: 533-537 (Pubitemid 29488531)
12. Ferguson SM, Brodkin JD, Lloyd GK, Menzaghi F. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology. 2000 ; 152: 295-303
13. George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: A preliminary study. J Clin Psychopharmacol. 2008 ; 28: 340-344
14. Glassman AH, Covey LS, Stetner F, Rivelli S. Smoking cessation and the course of major depression: a follow-up study. Lancet. 2001 ; 357: 1929-1932 (Pubitemid 32568334)
15. Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation and major depression. JAMA. 1990 ; 264: 1546-1549
16. Grant BF, Hasin DS, Chou P, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States. Arch Gen Psych. 2004 ; 61: 1107-1115
17. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: How did it change between 1990 and 2000?. J Clin Psych. 2003 ; 64: 1465-1475 (Pubitemid 41270106)
18. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009 ; 339: b3805 - b3805
19. Hitsman B, Borrelli B, McChargue DE, Spring B, Niaura R. History of depression and smoking cessation outcome: A meta-analysis. J Consult Clin Psychol. 2003 ; 71: 657-663 (Pubitemid 36897398)
20. Husky MM, Mazure CM, Paliwal P, McKee SA. Gender differences in the comorbidity of smoking behavior and major depression. Drug Alcohol Depend. 2008 ; 93: 176-179 (Pubitemid 350236582)
21. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003 ; 289: 3095-3105 (Pubitemid 37432885)
22. Kinnunen T, Henning L, Nordstrom BL. Smoking cessation in individuals with depression: Recommendations for treatment. CNS Drugs. 1999 ; 11: 93-103 (Pubitemid 29113638)
23. Klerman GL, Weissman MM. The course, morbidity, and costs of depression. Arch Gen Psych. 1992 ; 49: 831-834
24. Laje RP, Berman JA, Glassman AH. Depression and nicotine: Preclinical and clinical evidence for common mechanisms. Curr Psych Rep. 2001 ; 3: 470-474
25. Lasser K, Boyd JW, Woolhander S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000 ; 284: 2606-2610
26. Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, et al. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Therapeutics. 2008 ; 14: 266-277
27. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology. 2001 ; 155: 315-322 (Pubitemid 32477289)
28. Luppa M, Heinrich S, Angermeyer MC, Konig HH, Riedel-Heller SG. Cost-of-illness studies of depression: a systematic review. J Affect Disord. 2007 ; 98: 29-43 (Pubitemid 46048916)
29. Mathew SJ, Charney DS. Publication bias and the efficacy of antidepressants. Am J Psych. 2009 ; 166: 140-145
30. McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: A double-blind, placebo-controlled trial. Psychopharmacology. 2006 ; 189: 125-133 (Pubitemid 44607266)
31. McKee SA, Maciejewski PK, Falba T, Mazure CM. Sex differences in the effects of stressful life events on changes in smoking status. Addiction. 2003a ; 98: 847-855 (Pubitemid 36688070)
32. McKee SA, Wall A-M, Hinson RE, Goldstein A, Bissonnette M. Effects of an implicit mood prime on the accessibility of smoking expectancies in college women. Psychol Addiction Behav. 2003b ; 17: 219-225 (Pubitemid 37153096)
33. Mineur YS, Somenzi O, Picciotto MR. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology. 2007 ; 52: 1256-1262 (Pubitemid 46527701)
34. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997 ; 349: 1498-1504 (Pubitemid 27216360)
35. Niaura R, Britt DM, Borrelli B, Shadel WG, Abrams DB, Goldstein MG. History and symptoms of depression among smokers during a self-initiated quit attempt. Nicotine Tobacco Res. 1999 ; 1: 251-257
36. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: An 8-week, open-label study. J Clin Psych. 2009 ; 70: 1026-1031
37. Picciotto MR, Addy NA, Mineur YS, Brunzell DH. It is not "either/or": Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol. 2008 ; 84: 329-342
38. Picciotto MR, Brunzell DH, Caldarone BJ. Effect of nicotine and nicotinic receptors on anxiety and depression. NeuroReport. 2002 ; 13: 1097-1106 (Pubitemid 34722033)
39. Popik P, Kozela E, Krawczyk M. Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Brit J Pharmacol. 2003 ; 139: 1196-1202 (Pubitemid 36920683)
40. Rabenstein RL, Caldarone BJ, Picciotto MR. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not b2- or a7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology. 2006 ; 189: 395-401 (Pubitemid 44772820)
41. Salin-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in non-smoking patients with major depression. J Clin Psych. 1996 ; 57: 387-389 (Pubitemid 26321988)
42. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry. 2002a ; 7: 525-535
43. Shytle RD, Silver AA, Sheehan KH, Sheehan DH, Sanberg PR. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depression Anxiety. 2002b ; 16: 89-92 (Pubitemid 35334663)
44. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology. 1985 ; 85: 367-370 (Pubitemid 15123115)
45. Takeuchi H, Yatsugi S, Hatanaka K, Nakato K, Hattori H, Sonoda R, et al. Pharmacological studies on YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT receptor 2A antagonistic activity. Eur J Pharmacol. 1997 ; 329: 27-35 (Pubitemid 27264854)
46. Targacept (2007) Targacept presents data from tridmac trial showing positive effects of mecamylamine as augmentation treatment for depressed patients, July 24. Available at: http://www.drugs.com/clinical-trials/targacept- presents-data-tridmac-trial-showing-positive-mecamylamine-augmentation- depressed-patients-1643.html.
47. Targacept (2009) Targacept presents data from highly successful phase 2b trial of TC-5214 as augmentation treatment for major depressive disorder, October 15. Available at: http://www.targacept.com/wt/page/pr-1255642681.
48. Thiebot MH, Martin P, Puech AJ. Animal behavioural studies in the evaluation of antidepressant drugs. Brit J Psych. 1992 ; Suppl 15: 44-50
49. Tizabi Y, Rezvani AH, Russell LT, Tyler KY, Overstreet DH. Depressive characteristics of FSL rats: Involvement of central nicotinic receptors. Pharmacol Biochem Behav. 2000 ; 66: 73-77 (Pubitemid 30317519)
50. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: A pooled analysis. Drug Safety. 2010 ; 33: 289-301
51. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008 ; 358: 252-260
52. Vazquez-Palacios G, Bonilla-Jaime H, Velazquez-Moctezuma J. Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine. Pharmacol Biochem Behav. 2004 ; 78: 165-169 (Pubitemid 38670525)
53. Vazquez-Palacios G, Bonilla-Jaime H, Velazquez-Moctezuma J. Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine. Prog Neuro-Psychopharmacol. 2005 ; 29: 39-46 (Pubitemid 40018203)
54. Walsh Z, Epstein A, Munisamy G, King A. The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. J Addict Dis. 2008 ; 27: 65-72
55. Wang PS, Simon GE, Kessler RC. Making the business case for enhanced depression care: the National Institute of Mental Health-Harvard work outcomes research and cost-effectiveness study. J Occupat Environ Med. 2008 ; 50: 468-475 (Pubitemid 351521621)
56. Wilhelm K, Wedgwood L, Niven H, Kay-Lambkin F. Smoking cessation and depression: Current knowledge and future directions. Drug Alcohol Rev. 2006 ; 25: 97-107 (Pubitemid 43308158)
57. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tobacco Res. 2008 ; 10: 1691-1715